Background {#Sec1}
==========

*Lactococcus garvieae* are Gram-positive cocci previously considered part of the genus *Streptococcus*. In 1985, these organisms were classified within the genus lactococci due to DNA-DNA hybridization studies and fatty acid profiles \[[@CR1]--[@CR3]\]. Currently, the genus *Lactococcus* contains 11 species \[[@CR4]\]. *L. garvieae* is associated with fish infections in warm water causing outbreaks of haemorrhagic sepsis in rainbow trout \[[@CR2], [@CR5]\]. These organisms have also been isolated from raw cow milk, goat cheese, fish, beef meat, poultry and pork meat \[[@CR6]\]. Human infections caused by *L. garvieae* have been reported in different countries and have been associated to ingestion of raw seafood. Indeed, a study by Wang et al. found that among four patients with invasive *L. garvieae* infection, three had ingested sea food contaminated by these organisms \[[@CR7]\]. Infective endocarditis (IE) is a known disease caused by *L. garvieae*, however, the true incidence of disease is difficult to assess since misidentification with other Gram-positive cocci like *Enterococcus* spp*.* and streptococci (employing different automatized diagnostic tools) has commonly been reported \[[@CR8], [@CR9]\]. Here, we report a case of *L. garvieae* IE and describe the risk factors associated with this disease, the diagnostic challenges to identify these organisms and therapeutic approaches used to treat these infections. We seek to provide clinicians with relevant and updated information on the diagnosis and management of IE caused by the genus *L. garvieae.*

We searched MEDLINE, EMBASE and LILACS using the following MeSH, major and free terms: "endocarditis", "endocarditis, bacterial", "endocarditis, subacute bacterial", "endocarditis bacteriana", "endocarditis bacteriana subaguda" and "lactococo", "lactococcus", "lactococcus lactis", "lactococcus garvieae", "lactococcus garvieae endocarditis". We selected all the articles in Spanish, English and French published before March 2018 that included case reports of endocarditis and *Lactococcus* in the titles.

Case presentation {#Sec2}
-----------------

A 50-year-old Asian man with history of rheumatic heart disease (without hypertension) and mechanical prosthetic mitral valve replacement 5 years before admission, dyslipidaemia and reflux esophagitis presented to the emergency room with severe bilateral occipital headache. He was diagnosed with an intracranial haemorrhage confirmed by CT brain. At the time of admission, his INR was within therapeutic range (2.35). After initial work up, the patient was hospitalized for 10 days and discharged without any residual neurologic sequelae. Atorvastatin was prescribed. No fever or elevation of the C reactive protein (CRP) or erythrocyte sedimentation rate (ESR) were identified during the admission. He worked as an accountant and had been living in the US for the past 30 years with no recent travel outside the US. Three weeks later, he complained of flu-like symptoms and oseltamivir was prescribed. A week later, the patient returned to the hospital with epistaxis, haematuria, and malaise without fever. Physical examination was unremarkable with normal neurologic exam, except for a pansystolic heart murmur. Blood tests showed elevated white blood count (14.5 × 10^9^/L) and serum creatinine of 1.54 mg/dl (Normal value: 0.8--1.2 mg/dl). CRP and ESR were also elevated (34.5 mg/dl and 75 mm/h, respectively). A Chest X ray was found without acute abnormalities and the urine analysis showed no abnormalities. Three days after admission, blood cultures were positive for Gram-positive cocci in chains in 4 out of 4 bottles. Transthoracic echocardiography was inconclusive, but a transoesophageal echocardiography (TEE) revealed a 0.8 cm vegetation on the ventricular side of the native aortic valve without valve dysfunction, confirming the diagnosis of IE. Empirical intravenous antibiotic therapy was started with vancomycin 30 mg/kg/day in divided doses and gentamicin 3 mg/kg/day. The organism was recovered on blood agar and was identified by MALDI-TOF as *Lactococcus garvieae*. Susceptibility testing showed resistance to clindamycin, whereas it was susceptible to penicillin (MIC 0.25 μg/ml), ceftriaxone (MIC 0.25 μg/ml), vancomycin (MIC 1.5 μg/ml) and levofloxacin (MIC 2 μg/ml). With these results, vancomycin was switched to ceftriaxone 2 g IV twice daily plus gentamicin as combination therapy for the first 2 weeks. This regimen was chosen based on previous cases since no specific guidelines exist on how to treat these organisms. Gentamicin was stopped after two weeks and ceftriaxone was continued for 4 additional weeks pending a surgical decision. In the setting of intracranial bleed and IE, rupture of a mycotic aneurysm was highly suspected and the patient was considered a possible surgical candidate for aortic valve replacement. CT angiography of the brain (5 weeks after the initial episode of intracranial bleed) showed encephalomalacia in the left parietal and occipital lobes with subacute to chronic haemorrhage, with no mycotic aneurysms. After several discussions, the stroke team agreed on resuming anticoagulation with heparin IV drip (considering that the patient had a "chronic" bleed without active haemorrhage and that the risk of embolism was high due to the presence of a mechanical heart valve and IE). It was also suggested postponing aortic valve replacement for at least 4 weeks after effective antimicrobial therapy. After 4 weeks of therapy, decrease of inflammatory markers (CRP to 8.5 mg/dl and ESR to 40 mm/h) was observed and repeat blood cultures were negative.

Upon further questioning, the patient admitted that his diet was rich in grilled fish. Additionally, he reported a long history of chronic epigastric pain for 5 years, for which he had been taking over the counter medicines. An esophagogastroduodenoscopy showed severe gastritis and reflux esophagitis. After 6 weeks of treatment for IE, the patient had clinical improvement with no recurrence of infection but repeat TEE revealed severe aortic valve insufficiency. He underwent mechanical aortic valve replacement without complications and cultures from the excised valve were sterile.

Discussion and conclusion {#Sec3}
=========================

Different clinical presentations of subacute IE make it challenging to make an early diagnosis of infection and can cause delays in appropriate treatment. In our case, treatment of IE was delayed due to low suspicion of the disease at presentation and the occurrence of the intracranial haemorrhage. Importantly, collection of blood cultures as soon as infection was suspected, led to isolation of *L. garvieae* and identification using MALDI-TOF.

A total of 25 cases of IE caused by *L. garvieae* were identified in the literature review \[[@CR8]--[@CR30]\]. Among the 25 cases of IE caused by *L. garvieae* (Table [1](#Tab1){ref-type="table"}), 58% were reported in men and the median age of presentation was 68 years. Median duration of symptoms before consulting was 14 days (IQR = 6.2--21). The most common reported symptoms were fever (68%) and chills (28%). Presence of heart murmurs was the most common finding in the physical examination (72%). Laboratory tests usually showed leucocytosis, elevated CRP and ESR. Echocardiogram was reported in 24 out of 25 cases and vegetations were identified in 83.3%. The mitral valve was the most frequently involved valve. Colonoscopy was performed in 5 cases, all of which reported colonic polyps. The median duration of antimicrobial therapy was 42 days (IQR 41--45.5).Table 1Clinical, microbiological and management characteristics of IE by *L. garvieae*ReferenceCountryAgeSexAssociated factors for IE by *L. garvieae* and comorbiditiesSymptoms and duration (days)Physical examinationLaboratories and Echocardiography (Vegetation size)IdentificationSusceptibilityTherapy and days of treatmentComplications and OutcomeClavero et al. 2017Chile72FAV fistulas, Diverticulosis, CKD, DM 2 and HTN, colonic polypsChills, fever (1)Fever, systolic murmur, pulmonary cracklesTEE: mitral vegetation (4 mm) Labs: Leucocytosis elevated CRP Colonoscopy: Colonic polypsLG: Vitek 2^¥^, MS and 16S rRNA PCR.MIC: VAN: 2 μg/ml, CTX 0.25 µg/ml PEN: 0.5 µg/ml. Kirby Bauer: Sensitive: ERY, CIP, SXT, AMC Resistant: CLI. Applying the criteria for B-haemolytic streptococciEmpiric: CLO + AMK Directed: VAN + GEN µg (NI)Shock, respiratory failure (Died)Lim and Jenkins 2017UK57MCooked fish, gallstones, renal stones, Colonic polypsFever weight loss (60)Pansystolic murmurTEE: mitral valve vegetation (NI) and regurgitation. Colonoscopy: Duodenal polypsLG: MSPEN MIC: 1 mg/L\
Etest BioMérieux, S: GEN 200 µg Oxoid by diffusion disc testing.AMX + GEN (42d) Valve replacementNo complications, (Alive)Landeloos et al. 2017Belgium82FProsthetic mitral valve, previous endocarditis, Cooked fish, colonic polyps, FA, HTN, Osteoporosis.Fever, hyporexia, dyspnoea (14)Bradycardia, Basal lung crepitations, reinforce caused S2TEE: mitral vegetation (10x5mm) Labs: Elevated CRP no leucocytosis. Colonoscopy: Colonic polyps.LG: MS, 16S rRNA PCR.NIEmpiric: CRO Directed: MXF Changed: PEN + GEN Ambulatory: AMX monotherapy (42d) No valve replacementNo complications (Alive)Bazemore et al. 2016USA45MMultiple substance abuse. Repair of aortic root aneurysm, Hepatitis C and cirrhosisMalaise, weakness (60)Fever, systolic murmurNo Echo reported.\
Leucocytosis, Elevated CRP and ESR.LG: MSE-test: sensitive to CRO and VAN Cut-off values for *S. bovis*Empiric: TZP + VAN\
Directed: CRO + GEN (NI) + Valve repairAortic valve dehiscence (Alive)Suh et al. 2016South Korea75FMitral valve prosthesis, eats sea fresh food.Dyspnoea (3)Holosystolic murmurTTE: mitral vegetation (16 mm) Labs: leucocytosis, Elevated CRPLG: Vitek 2^¥^, 16S rRNA PCR.MicroScan MICroSTREP plus panel: PEN 0.12 µg/ml, AMC: 0.5/0.25 µg/ml, CRO 0.25 µg/ml, CTX 0.25 µg/ml, MEM 0.06 µg/ml, VAN 1 µg/ml, LVX 1 µg/ml, CLI \> 0.5 mcg/ml (only R to CLI). E test (bioMérieux, Marcy lEtoile, France)\
PEN 0.75 mg/L, CRO 0.38 mg/L,\
TEC 0.125 mg/L. Susceptibility CLSI for viridans streptococci.Empiric: CRO + GEN + RIF Directed: TEC\
Changed: CRO monotherapy (40d)\
Aortic and mitral replacementHeart failure (Alive)Heras Cañas et al. 2015Spain68MProsthetic aortic valve, HTN, dyslipidaemia, Hodgkin lymphoma in remission, AV block.Fever, Dyspnoea (10)NITTE: mitral vegetations (NI).\
Laboratories: Leucocytosis, elevate CRP.LG: MS and 16S rRNA PCRStreptococci breakpoints:\
S: CTX: 0.38 µg/ml, ERY: 0.25 mg/dl, VAN 1 µg/ml, LVX 1.5 µg/ml, VAN, AMP, CTX, OXA.\
I: PEN-I MIC 0.75 µg/ml,\
R: CLI 1 µg/ml.Empiric: DAP + AMP + CRO Directed: DAP+AMP + CRO + GEN (NI) + Valve replacementAKI, Aortic valve dehiscence (Alive)Igneri et al. 2015USA83MProsthetic aortic valve, Recent dental intervention, CHF, CLL, Prostate cancer, Coarctation of aorta, CABGMalaise, fever, vomit, headache, cough, myalgia, diaphoresis (7)NITTE: Could not exclude vegetations,\
Labs: Leucocytosis, Elevated CRPNINIEmpiric: AMP + GEN\
Directed: CTX + GEN (42d)\
Valve surgeryNo complication, (Alive)Ortiz et al. 2014Spain70FNo risk factors or comorbiditiesDyspnoea (NI)Holosystolic murmur, feverTTE: mitral vegetation (NI) Labs: Leucocytosis and elevated CRPNIS: CTX, CIP, ERY, DAP, VAN.Empiric: AMC + GEN Directed: VAN monotherapy (42d)\
valve surgeryNo complications (Alive)Spain77FColorectal cancer, HTN, CLLBack pain, fever (2)Purpuric lesions in extremities, feverTEE: mitral and aortic vegetation (NI) Labs: NINIS: PEN, AMC, CIP, VAN.AMP + GEN (NI)\
No valve surgeryAKI, Heart failure (Died)Tsur et al. 2014Israel76MRaw fish, Prosthetic aortic valve, CHF, AF, DM 2, HTN, Oesophageal carcinoma.Constipation, fever (NI)Fever, Tachycardia, Systolic murmur.TEE: Vegetation biologic prosthetic valve (NI)\
Labs: LeucocytosisLactococcus: API 32 strep kit^a^, 16S rRNA PCRS: CRO and GEN.\
I: PEN\
R: CLIEmpiric: CRO\
Directed: CRO+ GEN (NI)\
No valve replacementNo complications (Alive)Rasmussen et al. 2014Sweden81MProsthetic aortic valve, rectal diverticulosis, CAD, CABG, AFMalaise, headache, dysphasia (NI)Fever, systolic murmur.TEE: vegetations mitral valve and prosthetic valve (NI)\
Labs: Elevated CRPLG: Vitek 2^¥^, 16S rRNA PCRPEN: 0.5 mg/L, TOB: 2 mg/L.PEN + TOB (28d)\
No valve replacementSubdural hematoma (Alive)Navas et al. 2013USA64MPrevious mitral valve repair, Dental intervention, CAD, Cardiac defibrillator, DM2, COPDFatigue, weight loss, hyporexia, weakness, fever (NI)NIEcho not specified: Aortic vegetationsLG: Vitek 2^¥^, 16S rRNA PCR and MS\
Wrong ID: Microscan^b^Streptococcus breakpoints:\
I: PEN and AMP\
R: CLIVAN monotherapy (42d)\
Aortic valve replacement. Removal of pacemakerIntracardiac device infection (Alive)Fleming et al. 2012USA68MProsthetic aortic valve, NHL in remission. Colonic polypsMigratory arthralgias, dyspnoea, hyporexia, fatigue, weight loss, fever (21)Systolic ejection murmur. Splinter haemorrhage in nails of left handEcho not specified: Vegetation mitral valve. (NI)\
Labs: Elevated CRP and ESR Colonoscopy: Colonic polypsLG: Vitek 2^¥^, 16S rRNA PCRBreakpoints for VGS:\
S: VAN, SAM, CRO, TZP\
R: AMP, GEN, CLI.Empiric: AMP + GEN\
Directed: VAN monotherapy (42d)\
No valve replacementNo information of complications (Died)Russo et al. 2012Italy63MAscending aorta and aortic valve replacement, previous endocarditis, HTN.Fever, chills, Pharyngodini, weakness. (7)Systolic murmur, hepatomegalyTEE: mitral vegetation (NI)\
Labs: Elevated CRPLG: API 32^b^, Vitek 2^¥^, 16S rRNA PCREUCAST Streptococci breakpoint:\
S: ERY/S: 0.125 μg/ml, CTX 0.5 μg/ml LVX: 0.5 μg/ml, AMP: 0.25 μg/ml, AMC: 0.5 μg/ml, CIP: 0.75 μg/ml, DAP: 0.125 μg/ml, GEN: 2 μg/ml VAN: 2 μg/ml TEC: 0.5 μg/ml\
I: PEN: 2 μg/ml\
R: CLI: \> 64 μg/ml, RIF \> 64 µg/mlEmpiric: VAN + GEN\
Directed: AMP monotherapy (14d)\
No valve replacementNo complications (Alive)Watanabe et al. 2011Japan55FNo risk factors or comorbiditiesMalaise, myalgia, fever (60)Systolic murmur, painful black induration in finger.TEE: Mitral vegetation (10 mm) Labs: No leucocytosis Elevated CRPLG: Rapid ID32 Strep. ^a^, 16S rRNAE test: (AB Biodisk, Dalvagen, Solna, Sweden): ERY 0.25 mg/L, CLI: \> 256, VAN: 0.38 mg/L, LZD: 2 mg/L, PEN 0.5 mg/L, CRO 0.38 1mg/L, GEN: 1.5 mg/L, STR: 64 mg/LEmpiric: PEN + GEN. Directed: CRO + GEN (63d) No valve surgerySeptic embolism, stroke, aspirative pneumonia (Alive)Zuily et al. 2011France64FMitral valve prosthesis, fresh seafood, Pacemaker, Hepatitis C cirrhosis,Fever (NI)Fever, Murmur.TEE: Mitral vegetations (NI) Labs: Elevated CRP and ESR. LeucocytosisLG: PCRNIAMX + GEN (42d)\
no surgeryNo complications (Alive)Wilbring et al. 2011Germany55MFish farmer, mechanical tricuspid valve prosthesis, periodontitisChills, fever, dyspnoea (14)MurmurTEE: Mechanical prosthetic valve vegetation (7x9mm)\
Labs: Leucocytosis and elevated CRPNINIInpatient: GEN + VAN + RIF ambulatory: LVX + AMC (56d)\
No valve replacementNo complications (Alive)Hirakawa et al. 2011Brazil58FMitral prosthetic valve, fish and cheese often. Dental prosthesis and recent gingival perforation. DM 2, HTN, DyslipidaemiaFever, chills, diaphoresis, erythematous nodules in hands and legs, myalgia, weakness. (6)Fever, Osler nodes on left hand and legs.TEE: No vegetations Labs: Elevated CRP and ESR no leucocytosis.LG: Not specified biochemical tests. PCR.S: PEN, GEN, VAN.\
R CLIVAN monotherapy (28d)\
No valve surgeryNo complications (Alive)Li et al. 2008Taiwan41MNo risk factors or comorbiditiesSlurred speech (1)Right hemiplegia loss of right body sensation, right positive Babinski sign, murmur, feverTEE: Mitral vegetation and rupture of chordae tendineae (NI)\
Labs: Leucocytosis and elevated CRPLG: Vitek 2^¥^, Automated Pheonix^c^, 16S rRNA PCR^e^I: PEN: 0.75 µg/ml.PEN + GEN (30d)\
Valve replacementSeptic emboli, stroke, shock (Alive)Yiu et al. 2007China67MHeart rheumatic disease, previous endocarditis, eats fresh fish, AFChills, fever (21)Fever, mitral regurgitation murmurTEE: Mitral vegetation (10x1mm) Labs: Elevated ESR NeutrophiliaNINIAMP monotherapy (42d)\
Valve replacementPartial rupture of mitral valve (Alive)Wang et al. 2006Taiwan72MKidney stones, mitral valve prolapse. Raw fish consumption, gastric ulcerFever, purpuric leg lesions (14)Systolic murmur.Echo not specified: Severe mitral regurgitation, prolapse of posterior mitral valve, echogenic mass on the posterior mitral valve Labs: No leucocytosis. Endoscopy: Gastric ulcerLG: ID32 STREP; BioMérieux, Hazelwood, MO, USA, 16S rRNA PCRNIPEN + GEN (42d)No complications (Alive)Vinh et al. 2006Canada80MDM2, Hyperlipidaemia, CAD, CHFDyspnoea, epigastric discomfort. (NI)Midsystolic murmurTEE: Aortic vegetations (24 mm) Labs: NIWrong ID: API 20^d^ (L. lactis), Vitek 2^¥^(Enterococcus), 16S rRNA PCRCLSI *Enterococcus spp*. breakpoints:\
S: PEN, CIP, OFX, LVX, TET, VAN.\
CLSI *Streptococcus spp.* breakpoints:\
S: AMP, VAN, GEN\
I: PEN\
R: CLIEmpiric inpatient: AMP\
Ambulatory: PEN and then switched to AMP again. Monotherapy (56d)\
Valve replacementNo complications (Alive)Fihman et al. 2005France86MProsthetic aortic valve, Cholecystectomy.Fever, right hip pain (21)Fever, respiratory distressTEE: Aortic vegetation (10 mm) Labs: Leucocytosis and elevated CRP.LG: API 32^a^, 16S rRNA PCRE test: MIC: PEN: 0.75 μg/ml, AMX: 0.5 μg/ml CTX: 0.38 μg/ml, VAN: 1.5 μg/ml, TEC: 0.38 μg/ml, CLI \>8 µg/mlInpatient: AMX + GEN Ambulatory: AMX monotherapy (49d)\
Valve repairNo complications (Alive)James et al. 2000UK56FAortic valve prosthesisLow back pain, chills, night sweat, weight loss, hyporexia (63)Low back tenderness, splinter haemorrhages In nails, murmurTTE: No vegetations Labs: Elevated ESR and CRP. No leucocytosisLG: API Strep ^f^With streptococci reference laboratory (Respiratory and systemic reference laboratory London UK).Empiric: VAN Directed: TEC monotherapy (56d)Osteomyelitis (Alive)Fefer et al. 1998USA84FPacemaker for heart block, Aortic valve prosthesis, omeprazole, hypertrophic cardiomyopathy, ITP, hypothyroidism.Hyporexia, weakness, dyspnoea (NI)Holosystolic murmur, bilateral pulmonary ralesTEE: Ruptured chordae tendineae. Labs: Leucocytosis. Negative colonoscopy.LG: Biochemical tests.NCCLS Staphylococcus spp. breakpoints:\
S: VAN, AMP, CROEmpiric: AMP + GEN Directed: CRO monotherapy (NI)Intracranial haemorrhage, Rupture of chordae tendineae (Died)*NI* No information, *AMK* amikacin, *AMX* amoxicillin, *AMC* amoxicillin-clavulanic acid, *AMP* ampicillin, *CFZ* cefazolin, *CDN* cefditoren, *CTX* cefotaxime, *CRO* ceftriaxone, *CEF* cephalothin, *CHL* chloramphenicol, *CIP* ciprofloxacin, *CLR* clarithromycin, *CLI* clindamycin, *DAP* daptomycin, *ERY* erythromycin, *GEN* gentamicin, *LVX* levofloxacin, *LZD* linezolid, *MEM* meropenem, *MXF* moxifloxacin, *OFX* ofloxacin, *PEN* penicillin, *TZP* piperacillin-tazobactam, *RIF* rifampin, *STR* streptomycin, *TEC* teicoplanin, *TET* tetracycline, *TOB* tobramycin, *SXT* trimethoprim-sulfamethoxazole, *VAN* vancomycin, *MIC* Minimal inhibitory concentration, *S* Sensitive, *I* Intermediate, *R* resistant, *VGS* Viridans Group Streptococci, *CKD* Chronic kidney disease, *AKI* Acute kidney injury, *DM2* Diabetes mellitus type 2, *AF* Atrial fibrillation, *CHF* Cardiac heart failure, *NHL* Non-Hodgkin Lymphoma, *COPD* Chronic obstructive pulmonary disease, *CLL* Chronic lymphocytic leukaemia, *CAD* Coronary artery disease, *CABG* Coronary artery bypass graft, *LG* Lactococcus garvieae a Manual API 32 strep kit, automated Vitek 2 kit with GP identification card (BioMérieux Marcy l'etoile, france), b Microscan walk away system (dade behring, inc., Sacramento, CA), c:Automated Phoenix system (Becton Dickinson Diagnostic systems, Franklin Lakes, NJ), d: API 20strep kit (BioMérieux), e: 500 16S ribosomal rRNA bacterial sequencing kit (PE applied Biosystems, Foster city, CA, USA) ABI PRISM 310 Genetic Analyzer (PE applied biosystems), f: API Strep (BioMérieux, Basngstoke, Hants, UK)

When compared to other Gram-positive microorganisms, *L. garvieae* seems to affect more frequently patients with prosthetic valves. In our review, 52% (*n* = 13) patients with *L garvieae* IE had prosthetic valves, while large cohorts of endocarditis caused by *Enterococcus* spp., *Streptococcus* spp., Coagulase negative Staphylococci (CoNS) and *S. aureus*, report prosthetic valve involvement in 15.3--35%, 16.3--17.2%, 28--32.2% and 15.3--16% of cases, respectively \[[@CR31]--[@CR33]\]. Complications of IE such as valve dehiscence or rupture, septic emboli, renal failure, shock, stroke and heart failure were reported in 50% (*n* = 12) of cases. Surgery for valve repair or replacement was performed in 48% of cases. The case fatality rate of *L. garvieae* IE was 16% (n: 4), which is low compared to that of other GPC such as *S. aureus* (44.4%), *Enterococcus* spp. (23%) and CoNS (33.4%), but comparable to that of streptococci IE (15.7%) \[[@CR32]\].

The ingestion of raw sea food or exposure to fish, the presence of colonic polyps and the repeated exposure to dairy products have been postulated to be risk factors for infection by *L. garvieae* \[[@CR7]\]. Less than half of patients with IE caused by *L. garvieae* reported ingestion of fish (including raw or cooked) \[[@CR7], [@CR15], [@CR19], [@CR23], [@CR24], [@CR26]--[@CR28], [@CR30]\] or were diagnosed with a concomitant GI disorder \[[@CR10], [@CR13], [@CR19]--[@CR21], [@CR24], [@CR28]--[@CR30]\]. Our patient reported both conditions. The most important predisposing factor in these patients appears to be the presence of previous valvular disease. Of note, colonoscopy may be considered in patients with *L. garvieae* IE to rule out colonic polyps.

For species identification, MALDI-TOF, 16S RNA PCR, API 32 strep kit (BioMérieux, Marcy l'Etoile, France), Vitek 2 kit with GP identification card (BioMérieux) and BD Automated Phoenix System seem to be reliable techniques for the identification of *L. garvieae* in our series. However, the Vitek 2 reported misidentification of *Enterococcus spp*. as *L. garvieae* in one case \[[@CR8]\]. In contrast, the API 20 Strep (BioMérieux, Marcy-l'Etoile, France) and Microscan walk away system (Dade Behring, inc., Sacramento, CA) often misidentified the genus *L. garvieae* \[[@CR8], [@CR9]\]. Since the therapeutic approach for enterococci may be different to that used for *Lactococcus*, confirmation of identification should be performed with a reliable method. As no breakpoints for antibiotic susceptibility have been determined for *Lactococcus spp.* by the CLSI or EUCAST, most authors used those for viridans-group streptococci (VGS), group B streptococci, *Enterococcus* spp. or *Staphylococcus* spp. With these breakpoints, most *L. garvieae* isolates show intermediate resistance to penicillin and resistance to clindamycin \[[@CR8], [@CR9], [@CR13], [@CR22]\].

In summary, IE caused by *L*. garvieae may be a life-threatening infection. The most important predisposing factor is previous valvular disease. An association with gastrointestinal disease and consumption of fish has been established. Reliable methods for identification of *L. garvieae* include MALDI-TOF, 16S RNA PCR, API 32 strep kit (BioMérieux, Marcy l'Etoile, France) and BD Automated Phoenix System. Based on prior case reports and our own patient case, the recommended antimicrobials for *L. garvieae* are ampicillin (2 g every 4 h), amoxicillin (200 mg/kg/day divided in 4--6 doses), ceftriaxone (2 g every 12--24 h) or vancomycin (30 mg/kg/day divided in 2--3 doses) as monotherapy or in combination with gentamicin (3 mg/kg/day). Doses were defined using the recommendations for the treatment of VGS and enterococcal IE published by the American Heart Association/Infectious Diseases Society of America (AHA-IDSA) and European Society of Cardiology guidelines \[[@CR34], [@CR35]\]. It is unclear if combination therapy is needed (in cases where aminoglycoside toxicity is an issue), given that 5 out of 25 patients with *L. garvieae* IE were treated with vancomycin \[[@CR9], [@CR15], [@CR17]\], teicoplanin \[[@CR17]\] or ampicillin \[[@CR8]\] monotherapy with good outcomes. Further, the majority of patients in the *L. garvieae* group who died were treated at some point with monotherapy and combination therapy.
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